Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA is a non-steroid eye drop specifically designed for treating the signs and symptoms of dry eye disease (DED) with a focus on inflammation associated with this condition, along with acquiring […]
Swiss pharmaceutical giant Novartis has wrapped up the previously announced $3.5 billion acquisition of Seattle-based biopharmaceutical firm Chinook Therapeutics, Inc. This deal propels Novartis deeper into the realm of kidney disease treatments, capitalizing on Chinook Therapeutics’ cutting-edge precision medicines. Chinook Therapeutics’ promising pipeline, boasting two advanced assets, atrasentan and zigakibart (BION-1301), specifically targets Immunoglobulin A […]
BeiGene, a global biotechnology firm, has revealed that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for tislelizumab. This treatment is intended for adult patients suffering from unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC) who have previously undergone platinum-based chemotherapy. “Tislelizumab is the first […]
Swiss pharmaceutical giant Novartis has acquired DTx Pharma, a preclinical stage biotechnology company based in California renowned for its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) platform, which addresses the delivery challenges of oligonucleotide therapeutics. This acquisition, including the revolutionary FALCON platform, will enhance the delivery of small interfering RNA (siRNA) therapeutics to tissues beyond the […]
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast ophthalmic solution) 5%, known for treating dry eye disease (DED) symptoms. The transaction, which includes a $1.75 billion upfront cash payment, will see the global eye health giant adding the lucrative product, which had sales of approximately […]
Aurobindo Pharma, along with its subsidiary Eugia Pharma Specialities has announced a voluntary sub-licensing agreement with Medicines Patent Pool (MPP) to develop and market Nilotinib Capsules. Originally developed by Novartis, Nilotinib Capsules are used for the treatment of chronic myeloid leukemia (CML) in 44 low and middle-income countries (LMIC). This agreement covers seven countries where […]
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around $3.5 billion. The acquisition will bring two late-stage medicines for rare, severe chronic kidney diseases into Novartis’ portfolio. It aligns with Novartis’ strategy to focus on innovative medicines and will […]
Harrow Health, an ophthalmic therapies developer, will acquire the exclusive US commercial rights to five FDA‑approved ophthalmic products from the Novartis group of companies for up to $175 million. Under the terms of the arrangement, the Nasdaq-listed Harrow will make a one-time payment of $130 million at closing and up to an additional $45 million […]
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy for advanced prostate cancer. Following the approval, Pluvicto has become the first targeted radioligand therapy to be commercially available to prevent advanced prostate cancer in individuals. Pluvicto in combination with androgen deprivation therapy (ADT) with […]
Dr. Reddy’s Laboratories has signed an exclusive sales and distribution agreement with Novartis India Limited (NIL) for the latter’s Voveran range, the Calcium range and Methergine in India. As per the agreement, Dr. Reddy’s Laboratories will hold exclusive rights to promote and distribute the two brands in India. The company said that it will leverage […]